BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...$1,415 $1,171 $1,561.3 10% Gilead Sciences Inc. (NASDAQ:GILD) / Johnson & Johnson (NYSE:JNJ) Complera emtricitabine/tenofovir/rilpivirine (Eviplera...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Neupogen filgrastim $1,398.0 $885.0 $1,180.0 -16% Gilead Sciences Inc. (NASDAQ:GILD)/Johnson & Johnson (NYSE:JNJ) Complera emtricitabine/tenofovir/rilpivirine (Eviplera...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...Gilead Sciences Inc. (NASDAQ:GILD) Germany's G-BA issues a final benefit assessment saying HIV drug Eviplera emtricitabine/tenofovir/rilpivirine...
BioCentury | Jul 14, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...Germany’s Federal Joint Commission (G-BA) issued a final benefit assessment saying HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from...
...for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, April 7). In 2012, G-BA said Eviplera...
...NASDAQ:GILD), Foster City, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Eviplera emtricitabine/tenofovir/rilpivirine ( Complera...
BioCentury | Apr 7, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that HIV drug Eviplera emtricitabine/tenofovir/rilpivirine...
...final assessment from Germany's Federal Joint Committee (G-BA) expected in mid-June. In 2012, G-BA said Eviplera...
...NASDAQ:GILD), Foster City, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Eviplera emtricitabine/tenofovir/rilpivirine ( Complera...
BioCentury | Apr 2, 2014
Company News

IQWiG rebuffs Gilead's HIV drug Eviplera

...and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that HIV drug Eviplera emtricitabine/tenofovir/rilpivirine...
...final assessment from Germany's Federal Joint Committee (G-BA) expected in mid-June. In 2012, G-BA said Eviplera...
BioCentury | Feb 10, 2014
Finance

Confident roll of the dice(r)

...$933.6M, while sales of HIV drug Truvada emtricitabine/tenofovir were down 2% to $814.1M. Complera emtricitabine/rilpivirine/tenofovir (Eviplera...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Dec 23, 2013
Clinical News

Complera regulatory update

...FDA approved an sNDA from Gilead for Complera emtricitabine/tenofovir/rilpivirine for use as an alternative regimen for...
...second antiretroviral regimen and have no current or past history of resistance to Complera components. Complera...
...City, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Complera ( Eviplera - EU) emtricitabine/tenofovir/rilpivirine...
Items per page:
1 - 10 of 61